Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation?

Aucejo, Federico; Rofaiel, George; Miller, Charles M.

doi:10.1016/j.jhep.2005.10.008

Cited by 44 publications

(31 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk factors for PTLD after liver transplant include EBV seronegativity, early age (especially children and adolescents), and high doses of immunosuppression and first year after transplant (11)(12)(13). In our case, 50% of recipients had EBV seronegativity prior to the liver transplant.…”

Section: Risk Factors For Ptld Developmentmentioning

confidence: 63%

Post-transplant lymphoproliferative disease in liver transplant recipients

et al. 2017

View full text Add to dashboard Cite

Introduction: Post-transplant lymphoproliferative syndrome (PTLD) is a rare and potentially life-threatening complication after liver transplantation. The aim of this study was to analyze the clinicopathologic features related to PTLD in a single institution after liver transplantation.Methods: Observational study where we have retrospectively analyzed 851 cases who underwent liver transplantation. Ten cases have developed PTLD. Their clinical-pathological characteristics and the treatment received have been analyzed.Results: PTLD incidence was 1.2% (10/851). The mean time from liver transplantation to PTLD diagnosis was 36 months (range 1.2 to 144 months). PTLD localization was extranodal in all cases, the most frequent location being intestinal. Seven cases showed a monomorphic lymphoma which in all cases was differentiated B cell lymphomas. Fifty per cent of the series were seropositive for Epstein-Barr virus. Five patients were alive at the time of the review. Among these patients, we observed three cases of complete remission and two cases of disease stabilization. The death rate was higher in the first year after diagnosis of PTLD.Conclusion: PTLD is a rare complication after liver transplantation, but it may pose a threat to the life of a liver transplant recipient. It is essential to identify patients at risk, to establish an early diagnosis and treatment that can change the outcome of the disease.

show abstract

Section: Risk Factors For Ptld Developmentmentioning

confidence: 63%

Post-transplant lymphoproliferative disease in liver transplant recipients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…[62][63][64] In this era of transplant, it is also believed that chronic HCV infection may lead to the development of PTLD by stimulating lymphoid tissue and clonal B cells proliferation. 10 One reason for this risk enhancement is reportedly the immunosuppressive treatment in these patients, owing to preventing rejection episodes that can lead to activation of chronic infections including HCV. In this study of international data, we pooled the existing data from HCV-infected PTLD LT to find any potential associations between HCV infection in PTLD patients and disease features, behavior, and prognosis.…”

Section: Discussionmentioning

confidence: 99%

“…[5][6][7] It is shown that the rate of PTLD development has unequivocal associations with the type of organ transplanted, the intensity of the immunosuppression, underlying disease, age, and the occurrence of viral infections, particularly Epstein-Barr virus (EBV). [8][9][10] It also has been suggested that hepatitis C virus (HCV) and/or cytomegalovirus, as cofactors of EBV infection, may increase the risk of PTLD. [11][12] Hepatitis C virus has been associated with several extrahepatic manifestations, most of which are through immunologic pathways.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C Virus Infection Can Affect Lymphoproliferative Disorders Only as a Cofactor for Epstein-Barr Virus in Liver Transplant Recipients: PTLD.Int Survey

Khedmat

Taheri²

2012

Exp Clin Transplant

View full text Add to dashboard Cite

“…57 Posttransplant lymphoproliferative disorders are the second most common malignancy in solid organ transplant, occurring in 0.9% to 2.6% of adult OLT recipients, with a higher than 10% incidence in pediatric OLT recipients. 55,58 The cumulative incidence of posttransplant lymphoproliferative disorders in adults is estimated at 1.5%, 1.9%, and 3.2% at 1, 5, and 10 years after OLT, with a mean time to diagnosis between 26 and 32 months. 52,55 Most cases (80%-90%) are associated with reactivation of or primary Epstein-Barr virus infection.…”

Section: Malignancymentioning

confidence: 99%

Long-term Medical Management of the Liver Transplant Recipient: What the Primary Care Physician Needs to Know

Singh

Watt

2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Recognition, management, and prevention of medical complications and comorbidities after liver transplant is the key to improved long-term outcomes. Beyond allograft-related complications, metabolic syndrome, cardiovascular disease, renal dysfunction, and malignancies are leading causes of morbidity and mortality in this patient population. Primary care physicians have an important role in improving outcomes of liver transplant recipients and are increasingly relied on for managing these complex patients. This review serves to assist the primary care physician in the long-term management issues of liver transplant recipients.

show abstract

Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation?

Cited by 44 publications

References 36 publications

Post-transplant lymphoproliferative disease in liver transplant recipients

Post-transplant lymphoproliferative disease in liver transplant recipients

Hepatitis C Virus Infection Can Affect Lymphoproliferative Disorders Only as a Cofactor for Epstein-Barr Virus in Liver Transplant Recipients: PTLD.Int Survey

Long-term Medical Management of the Liver Transplant Recipient: What the Primary Care Physician Needs to Know

Contact Info

Product

Resources

About